We next tested the hypothesis that the 7G5 TCR has pan-cancer recognition ability, in line with the reported activity of the parent CD8+ clone MC.7.G5 (25), by measuring the reactivity of 7G5.TCR-T to an extensive panel of cancer cell lines. This evidence concerns the gene CD8A and cancer.